FDA approves Sanofi and Regeneron’s Dupixent for atopic dermatitis in young children

The US Food and Drug Administration (FDA) has granted approval for Sanofi and Regeneron’s Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in children aged six months to five years.